Cost-Effectiveness of Rivaroxaban for the Prevention of Stroke in Patients With Non-Valvular Atrial Fibrillation – A Multinational Study

Value in Health - United Kingdom
doi 10.1016/j.jval.2013.03.1481
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Cost-Effectiveness of Apixaban for Stroke Prevention in Non-Valvular Atrial Fibrillation in Saudi Arabia

Annals of Saudi Medicine
Medicine
2019English

Pcv84 - Cost-Effectiveness Analysis of Apixaban Versus Edoxaban for Stroke Prevention in Non-Valvular Atrial Fibrillation Spanish Patients

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Primary and Secondary Prevention of Stroke and Systemic Embolism With Rivaroxaban in Patients With Non-Valvular Atrial Fibrillation

Heart and Vessels
Cardiovascular MedicineCardiology
2018English

Pcv75 - An Updated Cost-Effectiveness Pairwise Analysis of Apixaban and Warfarin for Stroke Prevention in Patients With Non- Valvular Atrial Fibrillation in France

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Comparative Pharmacoeconomic Analysis of Rivaroxaban and Warfarin Usage in Patients With Non-Valvular Atrial Fibrillation

Jounal of arrhythmology
2020English

PCV56 Cost-Effectiveness of Dabigatran Etexilate Versus Warfarin for Stroke Prevention in Patients With Non-Valvular Atrial Fibrillation Under the Private and Public Health Care System in Brazil

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2012English

Cost-Effectiveness of Apixaban Compared With Aspirin for Stroke Prevention in Atrial Fibrillation Among Patients Unsuitable for Warfarin

Circulation. Cardiovascular quality and outcomes
MedicineCardiovascular MedicineCardiology
2012English

Cost-Effectiveness Analysis of Apixaban Against Warfarin for Stroke Prevention in Patients With Nonvalvular Atrial Fibrillation in Japan

Clinical Therapeutics
Pharmacology
2015English

Pcv79 - Real-World Cost-Effectiveness of Rivaroxaban Compared With Vitamin K Antagonists in the Context of Stroke Prevention in Atrial Fibrillation in France

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy